Harrow, Inc. is an eyecare pharmaceutical company that discovers, develops, and commercializes ophthalmic prescription medications in the United States. The company operates through two primary segments: Branded products and ImprimisRx, an ophthalmology-focused compounding pharmacy. Its branded portfolio includes FDA-approved treatments such as IHEEZO, VEVYE, TRIESENCE, and MAXITROL, which address conditions affecting both the front and back of the eye, including dry eye disease, glaucoma, cataracts, and retinal diseases. The ImprimisRx segment provides customized compounded medications and operates as a mail-order pharmacy licensed across all 50 states. Harrow primarily serves U.S. eyecare professionals, aiming to provide accessible ophthalmic disease management solutions.
